PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma.
Adolescent
Adult
Antibodies, Monoclonal, Humanized
/ therapeutic use
Bone Neoplasms
/ diagnosis
Disease Progression
Female
Follow-Up Studies
Humans
Immune Checkpoint Inhibitors
/ therapeutic use
Male
Neoplasm Grading
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Retrospective Studies
Sarcoma
/ diagnosis
Soft Tissue Neoplasms
/ diagnosis
Treatment Outcome
Young Adult
adolescent
bone neoplasms
immunotherapy
sarcoma
young adult
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
09
11
2020
received:
02
09
2020
accepted:
01
12
2020
pubmed:
15
12
2020
medline:
30
11
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
Sarcomas represent 10%-15% of cancers in adolescent and young adult (AYA) patients, and survival for those with metastatic disease or relapse is poor. Immunotherapy with checkpoint inhibition has improved outcomes in multiple tumor types, but data in advanced sarcomas, particularly within the AYA population, are limited. We aim to evaluate response and toxicity for AYA patients with sarcoma treated with pembrolizumab. We retrospectively reviewed AYA patients with advanced bone and soft tissue sarcoma who received self-funded pembrolizumab between May 2015 and January 2019. Eighteen patients were identified. One patient with Ewing sarcoma had a sustained complete response to therapy. Two patients with alveolar soft part sarcoma received a clinical benefit from pembrolizumab: one had a radiological partial response with an excellent clinical response and one patient achieved stable disease. Four patients died of disease prior to first scheduled assessment and thus were not evaluable. The remaining eleven patients had progressive disease. The role of immunotherapy in AYA sarcoma warrants further investigation. Biomarkers of response need to be further evaluated in order to guide patient selection.
Sections du résumé
BACKGROUND
Sarcomas represent 10%-15% of cancers in adolescent and young adult (AYA) patients, and survival for those with metastatic disease or relapse is poor. Immunotherapy with checkpoint inhibition has improved outcomes in multiple tumor types, but data in advanced sarcomas, particularly within the AYA population, are limited.
AIM
We aim to evaluate response and toxicity for AYA patients with sarcoma treated with pembrolizumab.
METHODS AND RESULTS
We retrospectively reviewed AYA patients with advanced bone and soft tissue sarcoma who received self-funded pembrolizumab between May 2015 and January 2019. Eighteen patients were identified. One patient with Ewing sarcoma had a sustained complete response to therapy. Two patients with alveolar soft part sarcoma received a clinical benefit from pembrolizumab: one had a radiological partial response with an excellent clinical response and one patient achieved stable disease. Four patients died of disease prior to first scheduled assessment and thus were not evaluable. The remaining eleven patients had progressive disease.
CONCLUSION
The role of immunotherapy in AYA sarcoma warrants further investigation. Biomarkers of response need to be further evaluated in order to guide patient selection.
Identifiants
pubmed: 33314769
doi: 10.1002/cnr2.1327
pmc: PMC8451371
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Immune Checkpoint Inhibitors
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1327Informations de copyright
© 2020 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Lancet Oncol. 2017 Nov;18(11):1493-1501
pubmed: 28988646
Lancet Oncol. 2018 Mar;19(3):416-426
pubmed: 29370992
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Eur J Hum Genet. 2019 Feb;27(2):308-316
pubmed: 30353151
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Cancer Rep (Hoboken). 2021 Apr;4(2):e1327
pubmed: 33314769
J Adolesc Young Adult Oncol. 2011 Mar;1(1):37-42
pubmed: 26812567
Oncoimmunology. 2018 Mar 15;7(7):e1442168
pubmed: 29900051
Med Oncol. 2018 Aug 20;35(10):132
pubmed: 30128793
J Hematol Oncol. 2016 Jun 03;9(1):48
pubmed: 27259563
Clin Cancer Res. 2016 Aug 1;22(15):3810-20
pubmed: 26994145
Cancer Res Treat. 2019 Jul;51(3):1086-1097
pubmed: 30428640
JAMA Oncol. 2015 Sep;1(6):778-84
pubmed: 26203912
Clin Sarcoma Res. 2016 Dec 30;6:24
pubmed: 28042471
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Sarcoma. 2013;2013:168145
pubmed: 23554566
Br J Cancer. 2011 May 10;104(10):1544-50
pubmed: 21505457
Lung Cancer. 2020 Jul;145:95-104
pubmed: 32417680
Mol Cancer. 2018 Aug 23;17(1):129
pubmed: 30139382
J Glob Oncol. 2018 Sep;4:1-6
pubmed: 30241159
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Oncologist. 2018 Jan;23(1):71-83
pubmed: 28935774
J Clin Oncol. 2010 Nov 10;28(32):4850-7
pubmed: 20479411